- Home
- AKRO vs TGTX Comparison
AKRO vs TGTX Comparison
Compare AKRO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- TGTX
- Stock Information
- Founded
- AKRO 2017
- TGTX 1993
- Country
- AKRO United States
- TGTX United States
- Employees
- AKRO N/A
- TGTX N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- AKRO Health Care
- TGTX Health Care
- Exchange
- AKRO Nasdaq
- TGTX Nasdaq
- Market Cap
- AKRO 3.6B
- TGTX 4.2B
- IPO Year
- AKRO 2019
- TGTX 1995
- Fundamental
- Price
- AKRO $46.27
- TGTX $32.43
- Analyst Decision
- AKRO Strong Buy
- TGTX Strong Buy
- Analyst Count
- AKRO 8
- TGTX 5
- Target Price
- AKRO $80.38
- TGTX $45.00
- AVG Volume (30 Days)
- AKRO 915.6K
- TGTX 2.1M
- Earning Date
- AKRO 11-07-2025
- TGTX 11-03-2025
- Dividend Yield
- AKRO N/A
- TGTX N/A
- EPS Growth
- AKRO N/A
- TGTX N/A
- EPS
- AKRO N/A
- TGTX 0.36
- Revenue
- AKRO N/A
- TGTX $454,069,000.00
- Revenue This Year
- AKRO N/A
- TGTX $82.58
- Revenue Next Year
- AKRO N/A
- TGTX $44.99
- P/E Ratio
- AKRO N/A
- TGTX $88.81
- Revenue Growth
- AKRO N/A
- TGTX 30.96
- 52 Week Low
- AKRO $21.34
- TGTX $21.16
- 52 Week High
- AKRO $58.40
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- AKRO 51.29
- TGTX 59.06
- Support Level
- AKRO $41.80
- TGTX $31.29
- Resistance Level
- AKRO $45.44
- TGTX $33.33
- Average True Range (ATR)
- AKRO 1.97
- TGTX 1.16
- MACD
- AKRO 0.06
- TGTX 0.29
- Stochastic Oscillator
- AKRO 75.76
- TGTX 79.77
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.